← All trials
NCT02469857
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2015
- Primary completion
- Dec 1, 2018
- Completion date
- Mar 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 290
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Atox Bio LtdLead sponsor
- Harborview Injury Prevention and Research CenterOverall official - principal investigator
- Atox Bio LtdStudy director
- Department of Health and Human ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.